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Abstract Allometric scaling on the basis of bodyweight
raised to the power of 0.75 (AS0.75) is frequently used to
scale size-related changes in plasma clearance (CLp) from
adults to children. A systematic assessment of its applica-
bility is undertaken for scenarios considering size-related
changes with and without maturation processes. A physi-
ologically-based pharmacokinetic (PBPK) simulation
workflow was developed in R for 12,620 hypothetical
drugs. In scenario one, only size-related changes in liver
weight, hepatic blood flow, and glomerular filtration were
included in simulations of ‘true’ paediatric CLp. In a sec-
ond scenario, maturation in unbound microsomal intrinsic
clearance (CLint,mic), plasma protein concentration, and
haematocrit were also included in these simulated ‘true’
paediatric CLp values. For both scenarios, the prediction
error (PE) of AS0.75-based paediatric CLp predictions was
assessed, while, for the first scenario, an allometric expo-
nent was also estimated based on ‘true’ CLp. In the first
scenario, the PE of AS0.75-based paediatric CLp predic-
tions reached up to 278 % in neonates, and the allometric
exponent was estimated to range from 0.50 to 1.20
depending on age and drug properties. In the second sce-
nario, the PE sensitivity to drug properties and maturation
was higher in the youngest children, with AS0.75 resulting
in accurate CLp predictions above 5 years of age. Using
PBPK principles, there is no evidence for one unique
allometric exponent in paediatric patients, even in scenar-
ios that only consider size-related changes. As PE is most
sensitive to the allometric exponent, drug properties and
maturation in younger children, AS0.75 leads to increas-
ingly worse predictions with decreasing age.
Key Points
There is no evidence for a universal allometric
exponent for scaling drug plasma clearance (CLp)
from adults to children.
When scaling CLp to children, the prediction error
(PE) is not sensitive to the allometric exponent in
children above the age of 5 years, resulting in
accurate CLp predictions with allometric scaling in
this age range for drugs eliminated by glomerular
filtration or for drugs undergoing hepatic metabolism
when enzyme activity is close to adult values.
In children below the age of 5 years, the PE in scaled
CLp becomes increasingly more sensitive to the
allometric exponent, drug properties and maturation,
leading to biased CLp predictions with allometric
scaling.
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1 Introduction
Allometric scaling’s first main domain of application was
scaling of the basal metabolic rate between species, after
which a series of investigations (principally in mammals)
suggested that interspecies differences in the basal meta-
bolic rate were best described by a bodyweight-based
exponential relationship with an exponent close to 0.75
[1–7]. Several theories have been developed to support the
existence of a universal allometric scaling exponent
[8–11]; however, these theories have been criticized, and
discrepancies between the theory and observations have
been reported [12–18].
The use of the allometric equation was extended to the
scaling of size-related changes in clearance between species
[19] and thereafter to the scaling of clearance from adults to
children [20]. While different universal values [1, 21] for
the allometric exponent have been proposed, a value of 0.75
is commonly applied in order to scale clearance from adults
to children. While allometric scaling is applicable to both
plasma and whole blood clearance, in this work we focus on
allometric scaling of plasma clearance (CLp) using an
exponent of 0.75, as this is the most commonly used for
clearance parameters. This scaling approach will be referred
to as AS0.75 in this work. This approach is appealing
because it is a simple and fast method to scale paediatric
CLp. However, this use of AS0.75 relies on two important
implicit assumptions, i.e. the assumption of equivalence
between basal metabolic rate and clearance, and the
assumption of equivalence between inter- and intraspecies
scaling. As illustrated in Fig. 1, for each of these assump-
tions separately, AS0.75 was found not to be supported by
experimental data, challenging the belief of the strong
theoretical and empirical basis of AS when applied in
scaling paediatric clearance [22–31].
For the scaling of CLp in the paediatric population,
AS0.75 has been recognized as a useful tool to extrapolate
CLp from adult values to adolescents [32], while overpre-
dictions in children younger than 5 years [33], reaching up
to more than 200 and 3000 % in infants and premature
neonates, respectively, have been reported [34]. The latter
is often attributed to the maturational process occurring
simultaneously with growth at young ages [35], similar to
what was concluded for the intraspecies scaling of the basal
metabolic rate [22]. To cope with this, the estimation of a
maturation function (MF) in addition to AS0.75 has been
proposed [35]. Because of the high correlation between age
and size, and consequently the difficulty in disentangling
the influence of size-related changes from the influence of
age-related changes, their distinction has hitherto been
mainly driven by the AS0.75 theory, according to which all
changes in CLp that are not accounted for by AS0.75 are
due to maturation. Moreover, the accuracy of AS0.75 of
CLp from adults to children has been evaluated for a lim-
ited number of drugs and it is unknown how the accuracy is
impacted by various drug properties.
The aim of this study was to unravel in which situations
AS0.75 consistently leads to accurate paediatric CLp pre-
dictions. To perform a systematic investigation, we
developed a physiologically-based pharmacokinetic
(PBPK) workflow for a wide range of hypothetical drugs
cleared through hepatic metabolism or glomerular filtration
(GF), and explored two scenarios—a scenario including
size-related changes only, and a scenario including size-
related changes as well as maturational changes. This
methodology allowed for the disentanglement of the
impact of drug properties, size-related changes, and mat-
uration processes on the performance of AS0.75 in pre-
dicting paediatric CLp from adult values.
2 Methods
A PBPK simulation workflow was developed in R version
3.0.2 (Fig. 2). This workflow was used to investigate the
accuracy of AS0.75 in predicting paediatric CLp, simulated
based on PBPK principles, for a total of 12,620 hypothet-
ical drugs (X).
Fig. 1 Implicit assumptions
underlying the use of AS to
scale CLp from adults to
children. AS allometric scaling,
CLp plasma clearance
274 E. A. M. Calvier et al.
2.1 Hypothetical Drugs (X)
In the simulations, numerous different hypothetical drugs
were investigated to explore the dependence of AS0.75
predictive performance on drug properties, as drug prop-
erties have been shown to influence the predictive perfor-
mance of AS0.75 in interspecies scaling of clearance (see
Fig. 1). Five drug-specific properties were used to generate
a wide range of hypothetical drugs (X); namely, route of
elimination, type of binding plasma protein, affinity to the
plasma protein, blood to plasma partition coefficient (Kp),
and the unbound intrinsic clearance value of one micro-
gram of liver microsomes (CLint,mic). Thus, the design
space was a five-dimensional hypercube, with each drug
property corresponding to one dimension.
The two investigated routes of elimination were hepatic
metabolism and GF. The hypothetical drugs were exclu-
sively bound either to human serum albumin (HSA) or a1-
acid glycoprotein (AGP). The affinity to plasma proteins
were derived from the unbound drug fraction in plasma (fu)
in adults and the plasma concentration of the binding
plasma protein in adults [36], using equations derived from
Rodgers and Rowland [37]. The fu in adults ranged from
1 to 100 %, with eight equidistant intermediate values.
Because the fu is more frequently reported than drug affinity
to plasma protein, the fu in adults, together with the type of
binding plasma protein, was retained for drug categoriza-
tion. Kp values of 0, 1, 2, 3 and 4 were selected, reflecting
different extents of drug diffusion in the red blood cells.
CLint,mic ranged between 0.56 9 10
-3 and 0.209
L min-1 mg-1 microsomal protein [38], with 124 equidis-
tant intermediate values. The different CLint,mic values
reflect different affinities for and abundances of enzymes.
Hypothetical drugs undergoing hepatic metabolism were
generated based on all possible combinations of the
aforementioned drug properties, while hypothetical drugs
undergoing GF were generated by all possible combina-
tions of affinity to plasma protein and type of binding
plasma protein only, as CLint,mic and Kp do not impact their
clearance.
Fig. 2 PBPK simulation workflow investigating the predictive per-
formance of AS0.75 on the basis of bodyweight to the power of 0.75,
when scaling paediatric CLp from adult CLp values. The simulations
include two scenarios: scenario 1 includes size-related changes only,
while scenario 2 includes both size-related changes and maturation in
the PBPK-based predictions of paediatric CLp. Simulated CLp values
are functions of X representing drug-specific properties (i.e. fu, type of
binding plasma protein, CLint,mic, and Kp). Paediatric CLp predictions
also depend on S representing size-related changes (changes in liver
weight, hepatic blood flow, and glomerular filtration) and, in scenario
2, also on M, which represents maturational changes (changes in
plasma protein concentration, haematocrit and CLint,mic). PBPK
physiologically-based pharmacokinetic, CLp plasma clearance, fu
unbound drug fraction in plasma, CLint,mic unbound microsomal
intrinsic clearance, Kp blood to plasma partition coefficient
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2.2 Simulation Scenarios
Two different scenarios regarding maturation (scenario 1
and scenario 2) were included in the PBPK-based simula-
tion workflow, and an overview of these scenarios is dis-
played in Table 1.
The first scenario (scenario 1) was designed in order to
answer the question as to whether scaling using an allo-
metric exponent of 0.75 accounts for all size-related
changes in the processes underlying CLp in the paediatric
population. Therefore, for this scenario, only size-related
changes were included in the simulations of PBPK-based
‘true’ paediatric CLp values. Size-related changes (S) in-
cluded in the PBPK simulations are changes in liver
weight, hepatic blood flow, and GF rate (GFR) [see step 1
of the PBPK simulation workflow for details on size-re-
lated changes]. In this scenario, for drugs undergoing
hepatic metabolism, enzymes were considered to have
reached maturity (CLint,mic was set to be 100 % of the adult
value). Furthermore, for this scenario, only drugs that do
not bind to plasma proteins and which are in equilibrium
between plasma and red blood cells (Kp of 1) were included
in order to exclude the potential influence of maturational
changes on CLp (see Eqs. 15 and 22–24 in the electronic
supplementary material). This drug selection is equivalent
to a selection of probe drugs for which only size-related
changes would impact the clearance.
A second scenario (scenario 2) was designed to inves-
tigate how maturation processes influence the applicability
of AS0.75 in the paediatric population, in order to unravel
the conditions in which AS0.75 consistently leads to
accurate paediatric CLp predictions. Therefore, for this
scenario, size-related changes (S) were included in the
simulations of PBPK-based ‘true’ paediatric CLp values, as
well as maturation processes (M), which are believed not to
be corrected for by AS0.75. Maturation processes included
maturation in plasma protein concentration and haemat-
ocrit, as well as hepatic enzyme maturation (see step 1 of
the PBPK simulation workflow for details on maturation).
For this scenario, all hypothetical drugs were included.
2.3 Physiologically-Based Pharmacokinetic (PBPK)
Simulation Workflow
2.3.1 Step 1: PBPK-Based Simulations of ‘True’ Plasma
Clearance (CLp)
For both scenarios, PBPK principles were used to simulate
‘true’ CLp values for the hypothetical drugs with different
properties (X; see the 2.1 section) in term neonates aged
1 day, infants aged 1 and 6 months, children aged 1, 2, and
5 years, adolescents aged 15 years, and adults (Fig. 2). For
drugs undergoing hepatic metabolism, CLp was computed
using the dispersion model (Eqs. 1–6), with an axial dis-
persion number (DN) of 0.17 [39]. The dispersion model
was selected as it has been reported to better predict
clearance than the well-stirred model for high-clearance
drugs, which are also included in the hypothetical drugs,
while both models lead to equivalent clearance predictions
for the rest of the drugs [40]:
CLp ¼ CLB  B : P ð1Þ
CLB ¼ QH  EH ð2Þ
EH ¼ 1 FH ð3Þ
FH ¼ 4að1þ aÞ2exp ða 1Þ=2DNf g  ð1 aÞ2exp ðaþ 1Þ=2DNf g
ð4Þ
Table 1 Overview of the two scenarios investigated in the PBPK-based simulation workflow. PBPK physiologically-based pharmacokinetic
Scenario 1 Scenario 2
Aim and research
question
Investigation of AS0.75 theory
Does an allometric exponent of 0.75 account for size-
related changes in paediatric CLp?
Investigation of general applicability of AS0.75 in paediatrics
Under which conditions AS0.75 consistently leads to accurate
paediatric CLp predictions?
PBPK-based
‘‘true’’ CLp
Only size-related changes (S) were included in the
PBPK simulations of true CLp
S include changes in liver weight, hepatic blood flow,
and glomerular filtration rate
Both size-related changes (S) and maturation (M) were included
in the PBPK simulations of true CLp
M includes maturation in plasma protein concentration and in
haematocrit as well as hepatic enzyme maturation
Selection of
hypothetical
drugs
Selection of hypothetical drugs equivalent to a selection
of probe drugs for which only size-related changes
would impact the clearance, by retaining drugs with:
fu = 1
Kp = 1
The number of selected drugs:
undergoing GF was 1
undergoing hepatic metabolism was 126
All hypothetical drugs
The number drugs:
undergoing GF was 20
undergoing hepatic metabolism was 12600
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a ¼ ð1þ 4RN  DNÞ1=2 ð5Þ
RN ¼ ðfu=B : PÞ  CLint=QH ð6Þ
In these equations, CLp is the plasma clearance, B:P is
the blood to plasma ratio, CLB is the whole blood
clearance, QH is the hepatic blood flow, EH is the hepatic
extraction ratio, fu is the unbound drug fraction in plasma,
CLint is the hepatic intrinsic clearance, and DN is the
dispersion number. For drugs undergoing GF, CLp was
computed as the product of GFR [36] and fu.
Adult demographic values (height and weight) and
adult values for cardiac output were taken from the ICRP
annals [41]. CLint in adults was computed as the product
of CLint,mic, amount of microsomal protein per gram of
liver, and liver weight [36]. B:P in adults was derived
from the Kp value, adult haematocrit [42], and fu in adults.
CLint,mic, Kp and fu in adults were taken from the values
defined to generate the hypothetical drugs (see the 2.1
section).
Paediatric demographic values (height and weight) were
taken from the CDC growth charts [43], and paediatric
cardiac output values were compiled from Johnson et al.
[36]. Size-related changes in CLint were accounted for by
changes in liver weight, and size-related changes in GF
were accounted for by changes in GFR [36]. Maturation of
CLint was accounted for by selected extents of enzyme
maturation [36]. For all hypothetical drugs undergoing
hepatic metabolism, different extents of enzyme matura-
tion, ranging between 10 and 200 % of the adult CLint,mic
value, were investigated for each paediatric age. Addi-
tionally, scenarios were simulated with published enzyme
maturation values for different hepatic isoenzymes
[36, 44–47]. For these scenarios, values for enzyme mat-
uration in neonates aged 1 day are based on values for term
neonates. Fu was scaled from adults to children by
accounting for maturation in plasma protein concentration
(HSA and AGP) [36]. B:P was scaled from adults to
children by accounting for maturation in haematocrit [42]
and plasma protein concentrations [36].
The ‘true’ CLps herein simulated are a function of the
properties of the hypothetical drug (X), size-related changes
(S), and, in scenario 2 (*), maturation (M):
f ‘true’ CLp(X; S;MÞ. In order to allow for computation
across a wide parameter space and improve interpretability
of the results, single-point estimates of
f ‘true’ CLp(X; S;MÞ were studied by transforming X, S,
and M in categorical variables using typical values for the
model parameters. For the same reasons, variability or
uncertainty in demographic parameters or model parameters
was not taken into account. Details on all equations used in
the PBPK model and parameter values used in the simula-
tions can be found in the electronic supplementary material.
2.3.2 Step 2: AS0.75-Based Paediatric CLp Predictions
In the AS0.75 equation (Fig. 2), bodyweight (BW) is used
as a descriptor of size. AS0.75-based CLp predictions for
children [fAS0.75 - based paediatric CLpðX; SÞ] were
performed in both scenarios for all included combinations
of hypothetical drugs (X) and size-related changes (S),
using the AS0.75 relationship. For scenario 1, only drugs
that do not bind to plasma proteins (fu = 1) and which are
in equilibrium between plasma and red blood cells (Kp of
1) were included in order to exclude the potential influence
of maturational changes on CLp (see the 2.2 section, as
well as Eqs. 15 and 22–24 in the electronic supplementary
material).
In this AS0.75 relationship, the typical bodyweight for the
different investigated paediatric ages (BWpaediatrics) was
normalized to the bodyweight of a typical adult (BWadult).
The typical bodyweight for the different paediatric ages and
adults were kept the same as for the PBPK-based CLp sim-
ulations (see electronic supplementary material).
2.3.3 Step 3: Prediction Error (PE)
For both scenarios, the prediction error (PE) of AS0.75
using the fixed allometric exponent of 0.75 in predicting
‘true’ PBPK-based paediatric CLp was determined for all
included combinations of hypothetical drugs (X) and size-
related changes (S) [scenarios 1 and 2] and, where relevant,
maturation (M) [scenario 2]. For scenario 1, only drugs that
do not bind to plasma proteins (fu = 1) and which are in
equilibrium between plasma and red blood cells (Kp of 1)
were included in order to exclude the potential influence of
maturational changes on CLp (see the 2.2 section, as well
as Eqs. 15 and 22–24 in the electronic supplementary
material). Because this workflow relies on ‘true’ CLp pre-
dictions from simulations that do not take parameter
uncertainty into account, predictions leading to PEs within
an interval of ±30 % were considered accurate.
For both scenarios, results were categorized by age and
route of elimination (hepatic metabolism or GF). For sce-
nario 2, in which both size-related changes and maturation
were included, results were also categorized by type of
binding plasma protein and extent of enzyme maturation.
The fu, Kp, B:P, and extraction ratio were screened for
potential additional categorization.
2.3.4 Step 4: Determination of the True Allometric
Exponent in Scenario 1
To investigate patterns in potential misspecification by
AS0.75, which could be useful in deriving general rules
regarding the applicability of AS0.75, the true allometric
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exponent (H) was derived for the scenario including only
size-related changes (scenario 1); the true allometric
exponent H was determined by rearranging the AS0.75
equation (Fig. 2). For each of the hypothetical drugs of this
scenario, the PE obtained with AS0.75 was plotted against
the true allometric exponent in order to evaluate the impact
of the fixed 0.75 exponent instead of the true allometric
exponent on the predictions accuracy.
3 Results
3.1 Scenario 1
Figure 3 shows the PE of AS0.75 in predicting ‘true’
paediatric CLp versus the true allometric exponent for each
paediatric age for the scenario including size-related
changes only (scenario 1) in the simulations of PBPK-
based ‘true’ paediatric CLp values (see the 2.2 section).
Figure 3a shows the results for 126 drugs undergoing
hepatic metabolism only differing in their CLint,mic values,
and Fig. 3b shows the results for one drug undergoing GF,
as, for this scenario, only drugs that do not bind to plasma
proteins (fu = 1) and which are in equilibrium between
plasma and red blood cells (Kp of 1) were included in order
to exclude the potential influence of maturational changes
in these parameters on CLp (see the 2.1 and 2.2 sections, as
well as Eqs. 15 and 22–24 in the electronic supplementary
material). In this scenario, the true allometric exponent
ranged from 0.52 to 0.88 for drugs undergoing hepatic
metabolism, and from 0.50 to 1.20 for drugs undergoing
GF. For both elimination routes, the true allometric expo-
nent was higher in the youngest age groups. For drugs
undergoing hepatic metabolism, the true allometric expo-
nent also slightly increased with decreasing CLint,mic in
children aged 5 years and older, with opposite results in
children younger than 5 years of age.
The PE resulting from the use of the fixed allometric
exponent of 0.75 instead of the true allometric exponent
was higher in the youngest children. For drugs undergoing
hepatic metabolism, PEs mostly remained within the
±30 % limits, with highest values reaching up to 32 % in
children aged 6 months. However, for drugs undergoing
GF, PE was higher than 30 % in children aged 6 months,
and reached up to 278 % in neonates aged 1 day. More-
over, the absolute PE increased with decreasing CLint,mic in
children aged 5 years and older, while it decreased with
decreasing CLint,mic in children younger than 5 years of
age. For children aged 2 years and younger, drugs under-
going hepatic metabolism with similar true allometric
exponents were found to lead to increased PE with
decreasing age, showing a higher sensitivity of the PE to
the use of a fixed allometric exponent of 0.75 in younger
children.
3.2 Scenario 2
3.2.1 PE for Hypothetical Drugs Undergoing Hepatic
Metabolism
Figure 4 shows the PE for the AS0.75-based paediatric CLp
predictions in scenario 2 for drugs undergoing hepatic
metabolism. Results are categorized by age, type of bind-
ing plasma protein, and extent of enzyme maturation. The
extraction ratio in adults was found to be most predictive of
the PE compared with fu, Kp or B:P. For this reason, results
Fig. 3 PE of AS0.75 using the fixed allometric exponent of 0.75 in
predicting ‘true’ paediatric CLp versus the true allometric exponent
for each paediatric age, for drugs undergoing (a) hepatic metabolism
or (b) glomerular filtration in scenario 1, where only size-related
changes were included in the PBPK-based simulations of ‘true’
paediatric CLp. The values for the different ages are represented with
different colours. Colour intensity increases with CLint,mic values of
the hypothetical drugs (a). Dotted black lines indicate a PE of ±30 %.
PE prediction error, CLp plasma clearance, PBPK physiologically-
based pharmacokinetic, CLint,mic unbound microsomal intrinsic
clearance
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were also categorized by adult extraction ratio in boxplots,
displaying the maximum, third quartile, median, first
quartile and minimum PE for each category.
The PE range increased with decreasing age and was
wider for drugs binding to AGP than for drugs binding to
HSA. The more the enzyme maturation differed from
100 % of the adult CLint,mic value, the more the PE range
increased, leading to the smallest PE range for enzyme
maturation of 100 %. Enzyme maturation had less effect on
the PE for high extraction ratio drugs compared with low
extraction ratio drugs.
For drugs undergoing hepatic metabolism, AS0.75 led to
accurate predictions for all hypothetical drugs in adoles-
cents aged 15 years and children aged 5 years when
CLint,mic was between 75 % and 100 %, and at 100 % of
the adult value, respectively. In a situation where CLint,mic
is at 100 % of the adult value, ‘true’ CLp with a PE within
±30 % for all investigated ages is predicted only in cases
of drugs with a low extraction ratio and binding to HSA.
For the remaining drugs, the absolute PE ranged up to
50 % in children as young as 6 months of age, and even
higher in neonates. Regardless of age, AS0.75 performed
poorly in predicting ‘true’ paediatric CLp of drugs metab-
olized by enzymes for which maturation is at or below
50 % of the adult CLint,mic value, leading to overprediction
of more than 50 % for a large part of the investigated
hypothetical drugs.
Table 2 displays published CLint,mic maturation values
for hepatic isoenzymes for each paediatric age, together
with their corresponding category of PE for AS0.75-based
CLp predictions for all hypothetical drugs. Three PE cat-
egories were defined, with the PE range for all hypothetical
drugs lying within ±30 % (green), within ±50 % (orange),
and including absolute PE values higher than 50 % (red),
with PE values rounded to the tenth (i.e 32 % was rounded
to 30 %). The PE of AS0.75-based CLp predictions for all
hypothetical drugs was within ±30 % in children aged
5 years and older, except for one of the three cytochrome
P450 (CYP) 1A2 enzyme maturation patterns and one of
the two CYP2E1 enzyme maturation patterns published in
children aged 5 years. For neonates aged 1 day and infants
aged 1 month, the PE range systematically included
absolute values [50 % for hypothetical substrates of all
isoenzymes. Intermediate results were found for children
between 6 months and 2 years of age.
3.2.2 PE for Hypothetical Drugs Undergoing Glomerular
Filtration
Table 3 displays the PE of AS0.75-based CLp predictions
for each paediatric age and each hypothetical drug under-
going GF. Drugs undergoing GF only differed by their fu
and type of binding plasma protein. AS0.75 led to a PE
within ±30 % for all these drugs in children as young as
1 year of age, with the exception of those drugs highly
bound to AGP (adult fu B0.12 %) in children aged 1 and
2 years. AS0.75 predictions in neonates aged 1 day and
infants aged 1 month led to a PE of up to more than 100 %.
Figure 5 displays a summary of the results regarding the
applicability of AS0.75 to scale CLp from adults to chil-
dren. Scenarios for which AS0.75 led to accurate CLp
predictions were defined, including ages, enzyme matura-
tion and drug properties.
4 Discussion
In this study, a PBPK simulation workflow was developed
in order to systematically investigate, for the first time, the
accuracy of AS0.75-based paediatric CLp predictions for a
wide range of hypothetical drugs, undergoing hepatic
metabolism or GF. The use of a systematic approach
increases our current knowledge on the applicability of
AS0.75 to predict paediatric CLp based on adult values,
which has, until now, been based on studies of a limited
number of existing drugs and a limited number of observed
concentrations. The use of PBPK principles allowed for the
screening of the impact of size-related changes, maturation,
and drug properties on the accuracy of AS0.75-based
paediatric CLp predictions, which is not possible with other
methods. This allowed us to define scenarios, including
ages, drug properties (including elimination pathways), and
maturation, for which AS0.75 is likely to lead to accurate
paediatric CLp predictions (Fig. 5).
In contrast with previously proposed applications of
AS0.75 theory in the paediatric population [20], but in line
with more recent work [18], the current study shows that
there is no universal allometric exponent that can be used
to accurately scale size-related changes in CLp from adults
to children of various ages. Even when estimated in sce-
narios in which only size-related changes are included
(scenario 1), the allometric exponent was found to vary
from 0.50 to 1.20, changing with age and drug properties
(Fig. 3). The corresponding PE was found to be more
sensitive to the use of a fixed exponent of 0.75 among the
youngest children, leading to increased bias in very young
children, with values around 30 % for drugs undergoing
hepatic metabolism and up to 278 % for drugs undergoing
GF (Fig. 3).
The inaccurate paediatric CLp predictions resulting from
AS0.75 in the very young are often attributed to the
influence of the many maturation processes that are known
to occur in these children. Therefore, in model building,
AS0.75 is usually used in combination with an MF that
should account for these maturational changes, to describe
CLp in this population for a specific drug. However, in
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scenario 1, which did not include maturation in the PBPK-
based simulations of ‘true’ paediatric CLp, the PE of the
AS0.75-based CLp predictions was still large in children
aged 6 months and younger (ranging from 43 to 278 %) for
drugs undergoing GF. From this it can be concluded that in
these scenarios, when modelling CLp in very young chil-
dren using AS0.75 in combination with MF, the MF likely
also corrects for bias introduced by the use of a fixed
allometric exponent of 0.75. Therefore, while the use of
AS0.75 ? MF may prove to be a viable method in some
cases, there is no sufficient evidence to support its scientific
basis, either for predicting drug clearance between indi-
viduals of different ages or for covariate relationships in
model-building procedures. Moreover, there are no
grounds to reject the well-established data-driven (i.e.
stepwise covariate model building) strategies for the
inclusion of bodyweight in a paediatric pharmacokinetic
model, which have recently been used to develop more
flexible functions to accurately scale CLp across the entire
paediatric age range using only bodyweight in model
development [48–51].
As similarly reported for interspecies AS0.75 of CLp
[23–31] (Fig. 1), drug properties were found to impact the
accuracy of the predictions (Figs. 3 and 4). While drug
properties not amenable to AS0.75 could be defined in the
case of interspecies AS0.75 of CLp [23, 24], no unique
trends (in terms of direction and extent) in the impact of
drug properties on the PE were observed for AS0.75 of CLp
in paediatric patients as this impact varied with maturation
and size (Table 3 and Fig. 4).
We found that enzyme activity close to adult values is
a requirement for accurate AS0.75-based CLp predictions
at all paediatric ages, which is in agreement with previous
reports [44, 52]. However, mature enzyme activity alone
is not sufficient to lead to accurate AS0.75-based CLp
predictions, as, in children younger than 5 years, AS0.75
can lead to a PE[30 %, depending on the drug proper-
ties, even when enzyme activity is close to adult values
(Fig. 4). With the exception of certain publications on
CYP2E1 and CYP1A2, it is commonly believed that
hepatic enzymes are mature in children aged 5 years and
older (Table 2), which is in line with previous reports on
the use of AS0.75 to predict CLp in children older than
5 years of age [34, 53].
bFig. 4 PE for AS0.75-based CLp predictions of drugs undergoing
hepatic metabolism in scenario 2, where both size-related changes and
maturation were included in the simulations of ‘true’ paediatric CLp,
with enzyme maturation in CLint,mic ranging from 10 to 200 % of the
adult value. PE prediction error, CLp plasma clearance, CLint,mic
unbound microsomal intrinsic clearance
Table 2 Published enzyme maturation values and their corresponding PE category of AS0.75-based CLp predictions for drugs undergoing
hepatic metabolism for scenario 2
Numbers within cells correspond to the value of enzyme maturation, as a percentage of adult enzyme activity, for each age and isoenzyme. NA
was used when no data on enzyme maturation for the corresponding age and isoenzyme were reported. * Indicates replacement of missing
enzyme maturation values (NA) by 100 % when reported values in younger and older children were equal to 100 %. Colours indicate the PE
category, with PE range for all hypothetical drugs lying within ±30 % in green, within ±50 % in orange, and including absolute values higher
than 50 % in red. PE values were rounded to the tenth. PE prediction error, CLp plasma clearance
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Drugs undergoing GF were found to be amenable to
AS0.75 of CLp until a younger age, than drugs undergoing
hepatic metabolism. Our results show that clearance
through GF can be accurately predicted in children as
young as 1 year of age for all drugs, with the exception of
drugs highly bound to AGP (fu B0.12) in children aged
between 1 and 5 years. While this result seems in line with
previous findings that GFR reaches adult values at 8–12
months of age [54], we emphasize that secretion and
reabsorption processes are not yet included in the
simulations.
Sethi et al. [55] recently suggested that the fu for drugs
binding to albumin was smaller than what can be predicted
using MFs for albumin currently in use, in children younger
than 4 years of age. The underestimated fu in children would
impact the results but would not impact our conclusion.
Indeed, for children aged 3 months and younger, we found
that AS0.75 led to inaccurate CLp prediction for drugs
undergoing both hepatic metabolism and GF.
The use of a PBPK approach allowed for the disentan-
glement of size-related changes, drug properties, and
maturation processes due to its unique feature to
Fig. 5 Scenarios for which AS0.75-based paediatric CLp predictions are accurate, based on a PBPK simulation workflow. CLp plasma clearance,
PBPK physiologically-based pharmacokinetic
Table 3 PE for AS0.75-based
CLp predictions for each drug
binding to AGP or HSA and
undergoing glomerular filtration
in scenario 2, where both size-
related changes and maturation
were included in the simulations
of ‘true’ paediatric CLp. Colours
indicate the prediction error
categories for each drug. Three
prediction error categories were
defined, with PE lying within
±30 % in green, within ±50 %
in orange, and including
absolute values higher than
50 % in red. PE prediction
error, CLp plasma clearance,
AGP a1-acid glycoprotein, HSA
human serum albumin
282 E. A. M. Calvier et al.
incorporate multiple levels of information to predict CLp
for different paediatric ages. Over the past decade, the
scaling of an adult PBPK model to paediatric patients has
been proven to lead to accurate CLp predictions in children
[36, 46, 56, 57]. The investigation of hypothetical drugs in
the current study allowed the avoidance of bias in PBPK-
based CLp predictions due to the inaccurate measurements
of drug-specific parameters, such as fu, which can occur
when studying existing drugs [58]. The parameters defining
drug properties should be interpreted as apparent parame-
ters. For instance, a drug with a Kp of 0 could translate into
a drug that can enter membranes and red blood cells, but
for which distribution in red blood cells is not a limiting
factor for its metabolism in the hepatocytes (i.e. fast drug
repartitioning compared with the residence time of blood in
the capillaries [59]). This simulation workflow does not
account for illness, and different results might be expected
in patients for whom physiological changes, for instance in
AGP concentration or organ function, can impact the drug
clearance [60]. However, this allows for the investigation
of AS0.75 predictive performance without confounding
factors such as illness, sparse paediatric clinical data, or
bias in the estimation of adult CLp used in the AS0.75-
based paediatric CLp predictions.
The herein applied workflow is intended to give an
overview of the impact of drug properties (including
elimination pathways), size-related changes, and matura-
tion on the accuracy of AS0.75-based CLp predictions. To
do so, unrealistic enzyme maturation scenarios for part of
the paediatric ages, as well as uniform distribution of drug
properties (equidistant values), were included in the sim-
ulations using a global sensitivity analysis with a fractional
design. Indeed, keeping enzyme maturation scenarios the
same for different ages allows to differentiate between the
impact of age and enzyme maturation, thereby unraveling
an increased sensitivity of the accuracy of AS0.75-based
CLp predictions to enzyme maturation with decreasing age
(see Fig. 4). Therefore, the poor predictive performance of
AS0.75 in young children is not solely due to enzyme
immaturity in itself, but also due to an increased sensitivity
of drug clearance to enzyme maturation at that age.
Because this study was intended to be systematic and not
probabilistic, results were not weighted on the likelihood of
the investigated drug properties. This approach can be
considered a risk assessment, where rare drug properties
are considered as important as frequent drug properties.
5 Conclusions
Based on current PBPK knowledge, we found no evidence
for a universal allometric exponent for scaling CLp in
children. This finding holds even when only size-related
changes are considered and maturation of processes
underlying drug clearance are not taken into account. This
work reveals that AS0.75 accurately predicts CLp in chil-
dren over 5 years of age for drugs eliminated by GF and/or
undergoing hepatic metabolism, when enzyme activity is
close to adult values, due to the lack of sensitivity of PE to
the allometric exponent and to the drug properties in this
scenario.
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